Eupraxia Pharmaceuticals Stock Probability of Future Stock Price Finishing Over 6.8
| EPRX Stock | CAD 6.87 0.14 2.00% |
Eupraxia |
Eupraxia Pharmaceuticals Target Price Odds to finish over 6.8
The tendency of Eupraxia Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay above C$ 6.80 in 90 days |
| 6.87 | 90 days | 6.80 | about 18.35 |
Based on a normal probability distribution, the odds of Eupraxia Pharmaceuticals to stay above C$ 6.80 in 90 days from now is about 18.35 (This Eupraxia Pharmaceuticals probability density function shows the probability of Eupraxia Stock to fall within a particular range of prices over 90 days) . Probability of Eupraxia Pharmaceuticals price to stay between C$ 6.80 and its current price of C$6.87 at the end of the 90-day period is about 1.95 .
Assuming the 90 days trading horizon Eupraxia Pharmaceuticals has a beta of -0.34 suggesting as returns on the benchmark increase, returns on holding Eupraxia Pharmaceuticals are expected to decrease at a much lower rate. During a bear market, however, Eupraxia Pharmaceuticals is likely to outperform the market. Additionally Eupraxia Pharmaceuticals has an alpha of 0.7207, implying that it can generate a 0.72 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Eupraxia Pharmaceuticals Price Density |
| Price |
Predictive Modules for Eupraxia Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Eupraxia Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Eupraxia Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Eupraxia Pharmaceuticals is not an exception. The market had few large corrections towards the Eupraxia Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Eupraxia Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Eupraxia Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.72 | |
β | Beta against Dow Jones | -0.34 | |
σ | Overall volatility | 0.92 | |
Ir | Information ratio | 0.15 |
Eupraxia Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Eupraxia Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Eupraxia Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Eupraxia Pharmaceuticals had very high historical volatility over the last 90 days | |
| Net Loss for the year was (25.74 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Eupraxia Pharmaceuticals has accumulated about 35.46 M in cash with (29.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.66. | |
| Roughly 19.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Eupraxia Pharmaceuticals Secures Speaking Slots at Canaccord, Citi, Cantor, and H.C. Wainwright Conferences - Stock Titan |
Eupraxia Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Eupraxia Stock often depends not only on the future outlook of the current and potential Eupraxia Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Eupraxia Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 35.6 M | |
| Cash And Short Term Investments | 33.1 M |
Eupraxia Pharmaceuticals Technical Analysis
Eupraxia Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. Eupraxia Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Eupraxia Pharmaceuticals. In general, you should focus on analyzing Eupraxia Stock price patterns and their correlations with different microeconomic environments and drivers.
Eupraxia Pharmaceuticals Predictive Forecast Models
Eupraxia Pharmaceuticals' time-series forecasting models is one of many Eupraxia Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Eupraxia Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Eupraxia Pharmaceuticals
Checking the ongoing alerts about Eupraxia Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Eupraxia Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Eupraxia Pharmaceuticals had very high historical volatility over the last 90 days | |
| Net Loss for the year was (25.74 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Eupraxia Pharmaceuticals has accumulated about 35.46 M in cash with (29.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.66. | |
| Roughly 19.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Eupraxia Pharmaceuticals Secures Speaking Slots at Canaccord, Citi, Cantor, and H.C. Wainwright Conferences - Stock Titan |
Other Information on Investing in Eupraxia Stock
Eupraxia Pharmaceuticals financial ratios help investors to determine whether Eupraxia Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Eupraxia with respect to the benefits of owning Eupraxia Pharmaceuticals security.